The global microfluidics devices market size was estimated to be USD 32.76 billion in 2023 and is expected to reach USD 305.65 billion by 2034 with a CAGR of 22.51% during the forecast period 2024-2034. The market for microfluidics devices is poised for significant growth due to factors such as miniaturization and automation, the increasing demand for personalized medicine, advancements in healthcare and life sciences, rising investments in research and development, growing awareness of microfluidics technology, the drive for point-of-care diagnostics, drug discovery, and development initiatives, and the escalating incidence of chronic diseases.
Microfluidic devices allow for the downsizing of complicated laboratory procedures, lowering sample and reagent quantities required. The automation of these operations increases efficiency while decreasing the danger of human mistakes. Microfluidics contributes to the advancement of personalized medicine by allowing for high-throughput screening and analysis of individual patient samples. This helps to tailor treatment approaches based on unique genetic or molecular profiles. For instance, Agilent Technologies introduced the Agilent BravoTM Microfluidic Liquid Handling System in October 2023, which provides high-throughput automation for microfluidic processes.
By product, the microfluidic-based devices segment accounted for the highest revenue-grossing segment in the global microfluidics devices market in 2023 owing to the innovative applications across various industries, particularly in healthcare, where microfluidic-based devices demonstrated unparalleled efficiency in diagnostics, drug development, and personalized medicine, thus driving substantial market demand and revenue. For instance, in October 2023, Thermo Fisher Scientific Inc. introduced the KingFisher Flex Purification System, which uses microfluidic automation to purify nucleic acids. Additionally, the microfluidic components segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased adoption of microfluidic technology across diverse industries, with a particular emphasis on the development of advanced research tools, diagnostic devices, and drug delivery systems, highlighting the crucial role of microfluidic components in enabling precise fluid control and enhancing the overall efficiency of microfluidic systems.
By application, the in-vitro diagnostics segment accounted for the highest revenue-grossing segment in the global microfluidics devices market in 2023 owing to the growing demand for accurate and rapid diagnostic solutions, coupled with technological advancements in in-vitro diagnostic techniques, which led to widespread adoption in clinical laboratories and healthcare settings. For instance, in December 2023, Danaher Corporation introduced the Pall MicroSep AdvanceTM Microfiltration System, which uses microfluidics to purify biomolecules. Additionally, the pharmaceutical and life science research and manufacturing segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased emphasis on precision medicine, drug discovery, and biopharmaceutical manufacturing, wherein the adoption of advanced technologies, such as microfluidics, plays a pivotal role in enhancing research efficiency, optimizing production processes, and facilitating the development of innovative therapies, thereby driving robust growth in the pharmaceutical and life science research and manufacturing segment.
By end-user, the hospitals and diagnostic centers segment accounted for the highest revenue-grossing segment in the global microfluidics devices market in 2023 owing to the rising demand for advanced diagnostic technologies, the increasing prevalence of chronic diseases, and the growing trend toward decentralized healthcare services, which led to significant adoption of Microfluidics Devices in hospitals and diagnostic centers. For instance, in June 2023 Becton, Dickinson and Company launched the BD FACSymphonyTM Cell Analyzer, which is designed for high-throughput cell analysis using a microfluidic chip. Additionally, the pharmaceutical and biotechnology company segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding drug development pipelines, continuous advancements in biotechnology, and the increasing focus on precision medicine, driving heightened demand for Microfluidics Devices that facilitate efficient data analysis, genomic research, and personalized medicine initiatives, thereby propelling substantial growth in the pharmaceutical and biotechnology company segment.
North American region is anticipated to have the highest revenue share during the forecast period owing to the robust investments in research and development, a well-established healthcare infrastructure, and the presence of major pharmaceutical and biotechnology companies, which collectively contribute to the widespread adoption of bioinformatics services and technologies, positioning the North American region at the forefront with the highest revenue share in the forecast period. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on life sciences and biotechnology research, a rising trend of outsourcing bioinformatics services, burgeoning investments in healthcare infrastructure, and the continuous expansion of pharmaceutical and biotechnology sectors, all of which collectively drive accelerated adoption and propel the Asia Pacific region to grow at the fastest compound annual growth rate (CAGR) during the forecast period. For instance, in September 2023, PerkinElmer Inc. introduced the PerkinElmer ChemiDocTM MP Imaging System, which has an automated western blotting microfluidic cartridge.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Microfluidic devices allow for the downsizing of complicated laboratory procedures, lowering sample and reagent quantities required. The automation of these operations increases efficiency while decreasing the danger of human mistakes. Microfluidics contributes to the advancement of personalized medicine by allowing for high-throughput screening and analysis of individual patient samples. This helps to tailor treatment approaches based on unique genetic or molecular profiles. For instance, Agilent Technologies introduced the Agilent BravoTM Microfluidic Liquid Handling System in October 2023, which provides high-throughput automation for microfluidic processes.
By product, the microfluidic-based devices segment accounted for the highest revenue-grossing segment in the global microfluidics devices market in 2023 owing to the innovative applications across various industries, particularly in healthcare, where microfluidic-based devices demonstrated unparalleled efficiency in diagnostics, drug development, and personalized medicine, thus driving substantial market demand and revenue. For instance, in October 2023, Thermo Fisher Scientific Inc. introduced the KingFisher Flex Purification System, which uses microfluidic automation to purify nucleic acids. Additionally, the microfluidic components segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased adoption of microfluidic technology across diverse industries, with a particular emphasis on the development of advanced research tools, diagnostic devices, and drug delivery systems, highlighting the crucial role of microfluidic components in enabling precise fluid control and enhancing the overall efficiency of microfluidic systems.
By application, the in-vitro diagnostics segment accounted for the highest revenue-grossing segment in the global microfluidics devices market in 2023 owing to the growing demand for accurate and rapid diagnostic solutions, coupled with technological advancements in in-vitro diagnostic techniques, which led to widespread adoption in clinical laboratories and healthcare settings. For instance, in December 2023, Danaher Corporation introduced the Pall MicroSep AdvanceTM Microfiltration System, which uses microfluidics to purify biomolecules. Additionally, the pharmaceutical and life science research and manufacturing segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased emphasis on precision medicine, drug discovery, and biopharmaceutical manufacturing, wherein the adoption of advanced technologies, such as microfluidics, plays a pivotal role in enhancing research efficiency, optimizing production processes, and facilitating the development of innovative therapies, thereby driving robust growth in the pharmaceutical and life science research and manufacturing segment.
By end-user, the hospitals and diagnostic centers segment accounted for the highest revenue-grossing segment in the global microfluidics devices market in 2023 owing to the rising demand for advanced diagnostic technologies, the increasing prevalence of chronic diseases, and the growing trend toward decentralized healthcare services, which led to significant adoption of Microfluidics Devices in hospitals and diagnostic centers. For instance, in June 2023 Becton, Dickinson and Company launched the BD FACSymphonyTM Cell Analyzer, which is designed for high-throughput cell analysis using a microfluidic chip. Additionally, the pharmaceutical and biotechnology company segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding drug development pipelines, continuous advancements in biotechnology, and the increasing focus on precision medicine, driving heightened demand for Microfluidics Devices that facilitate efficient data analysis, genomic research, and personalized medicine initiatives, thereby propelling substantial growth in the pharmaceutical and biotechnology company segment.
North American region is anticipated to have the highest revenue share during the forecast period owing to the robust investments in research and development, a well-established healthcare infrastructure, and the presence of major pharmaceutical and biotechnology companies, which collectively contribute to the widespread adoption of bioinformatics services and technologies, positioning the North American region at the forefront with the highest revenue share in the forecast period. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on life sciences and biotechnology research, a rising trend of outsourcing bioinformatics services, burgeoning investments in healthcare infrastructure, and the continuous expansion of pharmaceutical and biotechnology sectors, all of which collectively drive accelerated adoption and propel the Asia Pacific region to grow at the fastest compound annual growth rate (CAGR) during the forecast period. For instance, in September 2023, PerkinElmer Inc. introduced the PerkinElmer ChemiDocTM MP Imaging System, which has an automated western blotting microfluidic cartridge.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Product, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Microfluidics Devices Market Report 2023 - 2034
Microfluidics Devices Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Microfluidic-based Devices
- Microfluidic Components
Microfluidics Devices Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- In-vitro Diagnostics
- Pharmaceutical and Life Science Research and Manufacturing
- Therapeutics
Microfluidics Devices Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals and Diagnostic Centers
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
Microfluidics Devices Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Microfluidics Devices Market: Product Estimates & Trend Analysis
8. Microfluidics Devices Market: Application Estimates & Trend Analysis
9. Microfluidics Devices Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Microfluidics Devices Market
12. Europe Global Microfluidics Devices Market
13. Asia Pacific Global Microfluidics Devices Market
14. Latin America Global Microfluidics Devices Market
15. MEA Global Microfluidics Devices Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Hologic Inc.
- Siemens Healthineers
- GE Healthcare
- Philips Healthcare
- Fujifilm Holdings Corporation
- Carestream Health
- Planmed Oy
- IMS Srl
- Metaltronica S.p.A.
- Agfa-Gevaert Group
- General Medical Merate S.p.A.
- Konica Minolta Inc.
- Delphinus Medical Technologies Inc.
- ADANI Systems Inc.
- Allengers Medical Systems Limited.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 32.76 Billion |
| Forecasted Market Value ( USD | $ 305.65 Billion |
| Compound Annual Growth Rate | 22.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
